Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Not Confirmed
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Not Confirmed
Not Confirmed
29-31 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Industry Trade Show
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Industry Trade Show
Not Confirmed
29-31 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
15 May 2025
// PRESS RELEASE
https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld/
28 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250428674777/en/Boston-Pharmaceuticals-to-Present-the-Effect-of-Efimosfermin-Alfa-on-Collagen-Biomarkers-in-Patients-with-F2-and-F3-MASH-at-EASL-Congress-2025
23 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250423472313/en/Boston-Pharmaceuticals-to-Present-State-of-the-Art-Lecture-and-Poster-for-Once-monthly-Efimosfermin-Alfa-at-Digestive-Disease-Week-2025
15 Nov 2024
// BUSINESSWIRE
16 Oct 2024
// BUSINESSWIRE
06 Jun 2024
// BUSINESSWIRE
Details:
Through the acquisition, GSK will leverage Boston lead asset, BOS-580 (efimosfermin alfa). It is a phase III-ready, investigational specialty medicine to treat steatotic liver disease.
Lead Product(s): Efimosfermin Alpha
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: BOS-580
Study Phase: Phase IIProduct Type: Protein
Sponsor: GSK
Deal Size: $2,000.0 million Upfront Cash: $1,200.0 million
Deal Type: Acquisition May 14, 2025
Lead Product(s) : Efimosfermin Alpha
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : GSK
Deal Size : $2,000.0 million
Deal Type : Acquisition
GSK to Buy Liver Disease Drug for up to $2 Billion
Details : Through the acquisition, GSK will leverage Boston lead asset, BOS-580 (efimosfermin alfa). It is a phase III-ready, investigational specialty medicine to treat steatotic liver disease.
Product Name : BOS-580
Product Type : Protein
Upfront Cash : $1,200.0 million
May 14, 2025
Details:
The proceeds will be used to support Innate's pipeline, including CD123 targeting ANKET® SAR443579 (Bexatamig)/IPH6101 currently in development for relapsed or refractory acute myeloid leukemia.
Lead Product(s): Bexatamig,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: IPH6101
Study Phase: Phase I/ Phase IIProduct Type: Antibody
Sponsor: Sanofi
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 24, 2025
Lead Product(s) : Bexatamig,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Sanofi
Deal Size : $17.0 million
Deal Type : Financing
Innate Pharma Announces €15M Investment by Sanofi
Details : The proceeds will be used to support Innate's pipeline, including CD123 targeting ANKET® SAR443579 (Bexatamig)/IPH6101 currently in development for relapsed or refractory acute myeloid leukemia.
Product Name : IPH6101
Product Type : Antibody
Upfront Cash : Undisclosed
April 24, 2025
Details:
Innate will regain its rights on CD123 targeting ANKET® SAR443579 (Bexatamig)/IPH6101 currently in development for relapsed or refractory acute myeloid leukemia.
Lead Product(s): Bexatamig,Azacitidine,Venetoclax
Therapeutic Area: Oncology Brand Name: IPH6101
Study Phase: Phase I/ Phase IIProduct Type: Antibody
Sponsor: Sanofi
Deal Size: $1,455.1 million Upfront Cash: $26.4 million
Deal Type: Termination April 23, 2025
Lead Product(s) : Bexatamig,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Sanofi
Deal Size : $1,455.1 million
Deal Type : Termination
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
Details : Innate will regain its rights on CD123 targeting ANKET® SAR443579 (Bexatamig)/IPH6101 currently in development for relapsed or refractory acute myeloid leukemia.
Product Name : IPH6101
Product Type : Antibody
Upfront Cash : $26.4 million
April 23, 2025
Details:
IPH4102 (lacutamab) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, being evaluated for cutaneous T-cell lymphoma and peripheral T cell lymphoma.
Lead Product(s): Lacutamab
Therapeutic Area: Oncology Brand Name: IPH4102
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2025
Innate Wins FDA Breakthrough Status for Lacutamab in Sézary Syndrome
Details : IPH4102 (lacutamab) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, being evaluated for cutaneous T-cell lymphoma and peripheral T cell lymphoma.
Product Name : IPH4102
Product Type : Antibody
Upfront Cash : Inapplicable
February 17, 2025
Details:
IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 to treat neoplasms.
Lead Product(s): IPH4502
Therapeutic Area: Oncology Brand Name: IPH4502
Study Phase: Phase IProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2025
Innate Pharma Doses First Patient in Phase 1 Study of IPH4502 in Advanced Solid Tumors
Details : IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 to treat neoplasms.
Product Name : IPH4502
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 27, 2025
Details:
BOS-580 (efimosfermin alfa), is a once-monthly, subcutaneous injection of a long-acting variant of human FGF21 that regulates metabolic pathways in patients with MASH.
Lead Product(s): Efimosfermin Alpha
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: BOS-580
Study Phase: Phase IIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2024
Lead Product(s) : Efimosfermin Alpha
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Boston's Monthly Mash Prospect Hits Goal in Phase 2
Details : BOS-580 (efimosfermin alfa), is a once-monthly, subcutaneous injection of a long-acting variant of human FGF21 that regulates metabolic pathways in patients with MASH.
Product Name : BOS-580
Product Type : Protein
Upfront Cash : Inapplicable
November 15, 2024
Details:
Araris biotech expands its ip portfolio with the acquisition of innate pharma’s portfolio of transglutaminase patents for the generation of antibody-drug conjugates.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: Araris Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Araris Biotech
Deal Size : Undisclosed
Deal Type : Acquisition
Araris Biotech Acquires Innate Pharma Patents For Antibody-Drug Conjugates
Details : Araris biotech expands its ip portfolio with the acquisition of innate pharma’s portfolio of transglutaminase patents for the generation of antibody-drug conjugates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 24, 2024
Details:
IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 to treat neoplasms.
Lead Product(s): IPH4502
Therapeutic Area: Oncology Brand Name: IPH4502
Study Phase: IND EnablingProduct Type: Antibody-drug Conjugate
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2024
Lead Product(s) : IPH4502
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innate Pharma Receives FDA Clearance for IND of IPH4502 in Solid Tumors
Details : IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 to treat neoplasms.
Product Name : IPH4502
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
September 23, 2024
Details:
IPH6101 (bexatamig), an investigational CD123 targeting NKp46/CD16-based natural killer cell engager. It is being evaluated for the treatment of R/R acute myeloid leukaemia .
Lead Product(s): Bexatamig
Therapeutic Area: Oncology Brand Name: SAR443579
Study Phase: Phase I/ Phase IIProduct Type: Antibody
Sponsor: Sanofi
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2024
Lead Product(s) : Bexatamig
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Innate Pharma Announces Updated Results from Ph 1/2 Blood Cancer Trial SAR443579/IPH6101
Details : IPH6101 (bexatamig), an investigational CD123 targeting NKp46/CD16-based natural killer cell engager. It is being evaluated for the treatment of R/R acute myeloid leukaemia .
Product Name : SAR443579
Product Type : Antibody
Upfront Cash : Inapplicable
June 18, 2024
Details:
IPH45, a preclinical stage, novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, which is being developed for tumors expressing Nectin-4.
Lead Product(s): IPH45
Therapeutic Area: Oncology Brand Name: IPH45
Study Phase: PreclinicalProduct Type: Other Large Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2024
Lead Product(s) : IPH45
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data
Details : IPH45, a preclinical stage, novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, which is being developed for tumors expressing Nectin-4.
Product Name : IPH45
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 03, 2024
ABOUT THIS PAGE